Kinoid® Technology

Applying vaccine technology to treat chronic diseases

Neovacs is developing new treatments for autoimmune and inflammatory diseases, using its proprietary technology, known as Kinoids®. These therapeutic vaccines use the patient’s own immune system to generate the production of natural antibodies neutralizing the overproduced cytokines (proteins) responsible for the disease. For example in lupus, the anti-interferon-alpha (IFNα) antibodies generated by IFN Kinoid target IFNα, which is the cytokine involved in lupus disease. Kinoids®are a combination of a targeted cytokine to a carrier protein to make it immunogenic.

INDUCING A SAFE AND EFFECTIVE POLYCLONAL RESPONSE FROM THE BODY’S OWN IMMUNE SYSTEM

 

 

techno (2)

 

WHY SHOULD YOU INVEST IN NEOVACS ?

GO TO THE INVESTORS SECTION